# Global Blood Therapeutics Inc. (GBT)

Source: https://www.quantisnow.com/company/GBT
Generated: 2026-11-08T06:46:06.758Z

- Ticker: GBT
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2015
- Website: gbt.com

## About

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. The company offers Oxbryta tablets, an oral, once-daily therapy for sickle cell disease (SCD). It is evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase 2a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing inclacumab, a novel human monoclonal antibody to treat vaso-occlusive crises; and GBT601, a hemoglobin polymerization inhibitor. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD) and beta thalassemia. The company was founded in 2011 and is headquartered in South San Francisco, California.

## Latest GBT news and filings

- 2025-04-21 20:05 UTC [Public Offering] [Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow Shareholders](https://www.quantisnow.com/insight/deep-track-capital-files-definitive-proxy-statement-and-sends-letter-5994600)
- 2025-02-19 14:00 UTC [Public Offering] [Deep Track Capital Nominates Four Highly Qualified Candidates for Election to Dynavax Technologies' Board of Directors at 2025 Annual Meeting](https://www.quantisnow.com/insight/deep-track-capital-nominates-four-highly-qualified-candidates-for-election-5895968)
- 2023-02-14 13:34 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Global Blood Therapeutics Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-global-blood-therapeutics-inc-4055545)
- 2023-02-09 15:59 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Global Blood Therapeutics Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-global-blood-therapeutics-inc-4030360)
- 2022-11-10 18:35 UTC [Market Chatter] [White House Says It Will Continue To Monitor Developments On Cryptocurrencies](https://www.quantisnow.com/insight/white-house-says-it-will-continue-to-monitor-developments-on-3666153)
- 2022-10-17 12:32 UTC [SEC Form 15-12G filed by Global Blood Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-global-blood-therapeutics-inc-3537345)
- 2022-10-06 20:20 UTC [SEC Form 4] [SEC Form 4: Patrick Deval L returned 9,037 shares to the company, closing all direct ownership in the company to cover withholding tax](https://www.quantisnow.com/insight/sec-form-4-patrick-deval-l-returned-9037-shares-to-3505019)
- 2022-10-06 20:20 UTC [SEC Form 4] [SEC Form 4: Thompson Alexis A. returned 3,308 shares to the company, closing all direct ownership in the company to satisfy tax liability](https://www.quantisnow.com/insight/sec-form-4-thompson-alexis-a-returned-3308-shares-to-3505017)
- 2022-10-06 20:20 UTC [SEC Form 4] [SEC Form 4: Morrison Scott W returned 6,637 shares to the company, closing all direct ownership in the company (tax withholding)](https://www.quantisnow.com/insight/sec-form-4-morrison-scott-w-returned-6637-shares-to-3505016)
- 2022-10-06 20:21 UTC [SEC Form 4] [SEC Form 4: Perry Mark L returned 37,865 shares to the company, closing all direct ownership in the company to satisfy withholding tax](https://www.quantisnow.com/insight/sec-form-4-perry-mark-l-returned-37865-shares-to-3505013)
- 2022-10-06 20:20 UTC [SEC Form 4] [SEC Form 4: Yarno Wendy L returned 11,437 shares to the company, closing all direct ownership in the company (withholding obligation)](https://www.quantisnow.com/insight/sec-form-4-yarno-wendy-l-returned-11437-shares-to-3505010)
- 2022-10-06 20:20 UTC [SEC Form 4] [SEC Form 4: Svoronos Dawn returned 5,376 shares to the company, closing all direct ownership in the company to satisfy withholding obligation](https://www.quantisnow.com/insight/sec-form-4-svoronos-dawn-returned-5376-shares-to-the-3505006)
- 2022-10-06 20:20 UTC [SEC Form 4] [SEC Form 4: Pizzo Philip A. returned 9,112 shares to the company, closing all direct ownership in the company (withholding tax)](https://www.quantisnow.com/insight/sec-form-4-pizzo-philip-a-returned-9112-shares-to-3505005)
- 2022-10-06 20:20 UTC [SEC Form 4] [SEC Form 4: Pierce Glenn returned 26,437 shares to the company, closing all direct ownership in the company to satisfy withholding obligation](https://www.quantisnow.com/insight/sec-form-4-pierce-glenn-returned-26437-shares-to-the-3505001)
- 2022-10-06 20:15 UTC [SEC Form 4] [SEC Form 4: Johnson David Lee gifted 22,000 shares and returned 34,384 shares to the company, closing all direct ownership in the company (withholding obligation)](https://www.quantisnow.com/insight/sec-form-4-johnson-david-lee-gifted-22000-shares-and-3504937)
- 2022-10-06 20:15 UTC [SEC Form 4] [SEC Form 4: Smith-Whitley Kim returned 5,980 shares to the company, closing all direct ownership in the company to satisfy withholding obligation](https://www.quantisnow.com/insight/sec-form-4-smith-whitley-kim-returned-5980-shares-to-the-3504936)
- 2022-10-06 20:15 UTC [SEC Form 4] [SEC Form 4: Krehlik Carrie returned 6,716 shares to the company, closing all direct ownership in the company (withholding tax)](https://www.quantisnow.com/insight/sec-form-4-krehlik-carrie-returned-6716-shares-to-the-3504933)
- 2022-10-06 20:15 UTC [SEC Form 4] [SEC Form 4: Habibizad Nazila returned 39,680 shares to the company, closing all direct ownership in the company (for withholding tax)](https://www.quantisnow.com/insight/sec-form-4-habibizad-nazila-returned-39680-shares-to-the-3504931)
- 2022-10-06 20:15 UTC [SEC Form 4] [SEC Form 4: Love Ted W returned 922,618 shares to the company, closing all direct ownership in the company to satisfy withholding obligation](https://www.quantisnow.com/insight/sec-form-4-love-ted-w-returned-922618-shares-to-3504930)
- 2022-10-06 20:15 UTC [SEC Form 4] [SEC Form 4: Choi Jung returned 251,672 shares to the company, closing all direct ownership in the company to cover withholding tax](https://www.quantisnow.com/insight/sec-form-4-choi-jung-returned-251672-shares-to-the-3504929)
- 2022-10-06 20:15 UTC [SEC Form 4] [SEC Form 4: Farrow Jeffrey S returned 26,739 shares to the company, closing all direct ownership in the company to satisfy withholding tax](https://www.quantisnow.com/insight/sec-form-4-farrow-jeffrey-s-returned-26739-shares-to-3504926)
- 2022-10-06 20:15 UTC [SEC Form 4] [SEC Form 4: Suvari Tricia Borga returned 43,077 shares to the company, closing all direct ownership in the company to cover taxes](https://www.quantisnow.com/insight/sec-form-4-suvari-tricia-borga-returned-43077-shares-to-3504921)
- 2022-10-05 20:41 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Global Blood Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-global-blood-therapeutics-inc-3499389)
- 2022-10-05 20:40 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Global Blood Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-global-blood-therapeutics-inc-3499383)
- 2022-10-05 20:39 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Global Blood Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-global-blood-therapeutics-inc-3499376)
- 2022-10-05 20:39 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Global Blood Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-global-blood-therapeutics-inc-3499375)
- 2022-10-05 20:39 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Global Blood Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-global-blood-therapeutics-inc-3499365)
- 2022-10-05 20:38 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Global Blood Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-global-blood-therapeutics-inc-3499362)
- 2022-10-05 20:38 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Global Blood Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-global-blood-therapeutics-inc-3499358)
- 2022-10-05 20:37 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Global Blood Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-global-blood-therapeutics-inc-3499348)
- 2022-10-05 20:37 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Global Blood Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-global-blood-therapeutics-inc-3499346)
- 2022-10-05 20:35 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Global Blood Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-global-blood-therapeutics-inc-3499337)
- 2022-10-05 20:36 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Global Blood Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-global-blood-therapeutics-inc-3499335)
- 2022-10-05 20:32 UTC [SEC Form POSASR filed by Global Blood Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-posasr-filed-by-global-blood-therapeutics-inc-3499293)
- 2022-10-05 20:27 UTC [SEC Form POSASR filed by Global Blood Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-posasr-filed-by-global-blood-therapeutics-inc-3499154)
- 2022-10-05 20:21 UTC [SEC Form POSASR filed by Global Blood Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-posasr-filed-by-global-blood-therapeutics-inc-3499082)
- 2022-10-05 20:06 UTC [SEC Form 8-K] [Global Blood Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Events That Accelerate or Increase a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/global-blood-therapeutics-inc-filed-sec-form-8-k-entry-into-3498846)
- 2022-10-05 12:59 UTC [SEC Form 25-NSE filed by Global Blood Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-global-blood-therapeutics-inc-3496685)
- 2022-10-04 21:00 UTC [SEC Form 4] [SEC Form 4: Habibizad Nazila gifted 3,500 shares and converted options into 1,557 shares, decreasing direct ownership by 5% to 39,680 units](https://www.quantisnow.com/insight/sec-form-4-habibizad-nazila-gifted-3500-shares-and-converted-3493831)
- 2022-09-30 20:06 UTC [SEC Form 8-K] [Global Blood Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events](https://www.quantisnow.com/insight/global-blood-therapeutics-inc-filed-sec-form-8-k-submission-of-3478974)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/GBT
- Earnings history: https://www.quantisnow.com/earnings/GBT
- Dividend history: https://www.quantisnow.com/dividends/GBT
- Insider transactions: https://www.quantisnow.com/insiders/GBT
- Options chain: https://www.quantisnow.com/options/GBT
- SEC 8-K filings only: https://www.quantisnow.com/company/GBT/8-k
- RSS and alerts for GBT: https://www.quantisnow.com/docs/rss-feeds.md